Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Information source: Fred Hutchinson Cancer Research Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anaplastic Large Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia
Intervention: cyclophosphamide (Drug); etoposide (Drug); iodine I 131 tositumomab (Radiation); quality-of-life assessment (Procedure); peripheral blood stem cell transplantation (Procedure)
Phase: Phase 2
Status: Completed
Sponsored by: Fred Hutchinson Cancer Research Center Official(s) and/or principal investigator(s): Ajay Gopal, Principal Investigator, Affiliation: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Summary
This phase II trial is studying how well giving iodine I 131 tositumomab together with
etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating
patients with relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal
antibodies, such as iodine I 131 tositumomab, can find cancer cells and deliver radioactive
cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy,
such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Combining a
radiolabeled monoclonal antibody with combination chemotherapy before autologous stem cell
transplant may kill more cancer cells
Clinical Details
Official title: A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Progression-free survival
Secondary outcome: Overall survivalResponse rate Toxicity as assessed by Common Terminology Criteria (CTC) v 2.0
Detailed description:
PRIMARY OBJECTIVES:
I. To assess the progression-free survival of patients receiving 131 I labeled tositumomab
antibody, etoposide (VP-16) and cyclophosphamide (CY) followed by autologous
transplantation.
II. To examine the potential efficacy of 131 I labeled tositumomab antibody, etoposide
(VP-16) and cyclophosphamide (CY) followed by autologous transplantation.
SECONDARY OBJECTIVES:
I. To assess the overall survival of patients receiving 131 I labeled tositumomab antibody,
etoposide (VP-16) and cyclophosphamide (CY) followed by autologous transplantation.
II. To evaluate the toxicity and tolerability of the above therapy.
OUTLINE:
RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab intravenously
(IV) on day - 24 to determine biodistribution. Patients then receive therapeutic iodine I 131
tositumomab IV over approximately 40-60 minutes on day - 14 and are entered into radiation
isolation until day - 4.
CHEMOTHERAPY: Patients receive etoposide IV on day - 4 and cyclophosphamide IV on day -2.
AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell
transplant on day 0.
After completion of study treatment, patients are followed at 1, 3, 6, and 12 months and
then annually thereafter.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients must have a histologically confirmed diagnosis of lymphoma expressing the
cluster of differentiation (CD)20 antigen and generally must have failed at least one
prior standard systemic therapy; the exception will be mantle cell lymphoma (MCL)
patients, who may be enrolled while in first complete remission (CR) in accordance
with current transplant standard of care for these patients
- Note: Patients with clinically non-transformed follicular lymphomas do not require
repeat biopsies for immunophenotyping since these tumors are uniformly reactive with
the tositumomab antibody
- Patients must have tumor burdens < 500cc by computed tomography (CT) or magnetic
resonance (MRI) volumetric measurements and must not have splenomegaly at the time of
enrollment; splenomegaly will be defined as a spleen volume > 2 standard deviations
of the mean spleen volume to body weight ratio (mean = 3. 84 cc/kg, SD = 1. 53 cc/kg);
thus, patients with > 6. 9cc/kg will be defined as having splenomegaly; patients with
splenomegaly that is thought to be due to G CSF/GM-CSF effect and not due to
lymphomatous involvement of the spleen can been deemed eligible with the approval of
an investigator
- Patients must have normal renal function (creatinine [Cr] < 2. 0)
- Patients must have normal hepatic function (bilirubin < 1. 5mg/dL), with the exception
of patients thought to have Gilbert's syndrome, who may have a total bilirubin above
1. 5mg/dL
- All patients eligible for therapeutic study must have autologous hematopoietic stem
cells (2 x 10^6 CD34+ cells/kg) harvested and cryopreserved
- Patients must have an expected survival of > 60 days and must be free of major
infection
Exclusion Criteria:
- Circulating anti-mouse antibody (HAMA)
- Systemic anti-lymphoma therapy given within 30 days prior to anticipated treatment
date
- Inability to understand or give an informed consent
- Prior radiation > 20 Gy to any critical normal organ (e. g., lung, liver, spinal cord,
or over 25% of red marrow)
- Central nervous system lymphoma
- Other serious medical conditions considered to represent contraindications to
autologous stem cell transplant (ASCT) (e. g., active coronary artery disease,
pulmonary dysfunction [forced expiratory volume in 1 second (FEV1) < 70% expected,
Vital Capacity < 70% expected, diffusing capacity of the lung for carbon monoxide
(DLCO) < 50%, patient on supplemental oxygen], AIDS, etc.)
- Pregnancy
- Prior bone marrow or stem cell transplant
- Presence of circulating lymphoma cells by morphology or flow cytometry (>= 0. 1%) at
or near the time of peripheral blood stem cell (PBSC) collection if unpurged PBSC are
to be used
- Southwest Oncology Group (SWOG) performance status >= 2. 0
- Unable to perform self-care during radiation isolation
- Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma/well
differentiated lymphocytic lymphoma (ineligible because these tumors express very low
surface densities of CD20)
Locations and Contacts
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington 98109, United States
Additional Information
Starting date: February 1999
Last updated: August 4, 2014
|